TRPC6 CRISPR Activation Plasmid (h): sc-401205-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- TRPC6 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- TRPC6 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by TRPC6 CRISPR Activation Plasmid (h) and TRPC6 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the TRPC6 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: TRPC6 Antibody (B-10): sc-515837
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TRPC6 CRISPR Activation Plasmid (h) | sc-401205-ACT | 20 µg | $397.00 | |||
TRPC6 CRISPR Activation Plasmid (h2) | sc-401205-ACT-2 | 20 µg | $397.00 |
Human TRPC6 encodes a nonselective, Ca2+-permeable transient receptor potential cation channel that is activated downstream of phospholipase C signaling and diacylglycerol. TRPC6-mediated Ca2+ influx supports receptor-operated calcium entry, shaping intracellular calcium dynamics that regulate cytoskeletal remodeling, contractility, and gene transcription programs such as NFAT-dependent signaling. The channel is implicated in mechanosensitive and GPCR-linked pathways in kidney podocytes and vascular smooth muscle, with altered TRPC6 activity associated with proteinuric kidney disease phenotypes and cardiovascular remodeling. TRPC6 is also studied in contexts of calcium-dependent proliferation and migration, making it relevant to diverse cell signaling and ion channel research workflows.
TRPC6 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous TRPC6 expression without altering the underlying DNA sequence.
TRPC6 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the TRPC6 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the TRPC6 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous TRPC6 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native TRPC6 locus and enabling the study of TRPC6-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of TRPC6 pathway restoration in tumor cells with silenced or reduced TRPC6 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.